Program Book - Confex

ACR/ARHP Poster Session B
1398. Clinical-Pathological Correlates of Proliferative Lesions
in Lupus Nephritis. Claire Barber 1 , Murray B. Urowitz 2 ,
Dafna D. Gladman 3 , Joan E. Wither 4 , Carolina Landolt-
Marticorena 2 , Heather Reich 5 , Wendy Lou 6 , Jiandong Su 7 ,
Jonathan Yip 8 , Gan Qian 6 , David Thomas 9 , Samih Nasr 10 ,
Rohan John 8 , Ellie Aghdassi 8 and Paul R. Fortin 7 , 1 Mount
Sinai Hospital, Toronto, ON, 2 Toronto Western Hospital
and University of Toronto, Toronto, ON, 3 Toronto Western
Hospital, University of Toronto, Toronto, ON, 4 Toronto
Western Research Institute, University Health Network,
Toronto, ON, 5 The Toronto Western Hospital, Toronto, ON,
6
Dalla Lana School of Public Health, Toronto, ON, 7 Toronto
Western Hospital, Toronto, ON, 8 University Health Network,
Toronto, ON, 9 Nephrocor, Long Island, NY, 10 Division of
Anatomic Pathology, Mayo Clinic, Rochester
1399. Chronicity Index, Especially Glomerular Sclerosis, Is An
Independent Predictor of Renal Response Following
Immunosuppressive Treatment in Patients with Lupus
Nephritis. Dong-Jin Park 1 , Sung-Ji Lee 1 , Tae-Jong Kim 2 ,
Yong-Wook Park 2 and Shin-Seok Lee 1 , 1 Chonnam National
University Medical School, Gwangju, South Korea,
2
Chonnam National University Medical School and Hospital,
Gwangju, South Korea
1400. Asian Ethnicity Is Associated with Increased Disease
Severity in An Urban Australian SLE Cohort. Alberta Y.
Hoi, Vera Golder and Eric F. Morand, Monash University,
Melbourne, Australia
1401. Incidence and Prevalence of Systemic Lupus Erythematosus
in Buenos Aires, Argentina: A 11 Years Health Management
Organization Based Study. Soledad M. Valeiras 1 , Martin
F. Marchese 1 , Alejandro S. Talani 1 , Nicolas L. Avellaneda 1 ,
Alvaro Etchepare 1 , Patricio Etchepare 1 , Maria S. Plou 1 and
Enrique R. Soriano 2 , 1 Instituto Universitario, Escuela de
Medicina, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina, 2 Rheumatology Unit, Internal Medical Services,
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
1402. Long-Term Outcome of Lupus Nephritis in Asian Indians
Using Standard Therapy. Varun Dhir, Amita Aggarwal, Able
Lawrence, Vikas Agarwal and Ramnath Misra, Sanjay Gandhi
Post Graduate Institute of Medical Sciences, Lucknow,
Lucknow, India
1403. Soluble Form of Herpesvirus Entry Mediator (HVEM) Is
Elevated in Sera of Active Collagen-Vascular Diseases and
Might Be a New Biomarker of Disease Activity. Satoko Arai,
Kazuhiro Kurasawa, Harutsugu Okada, Takayoshi Ohwada,
Reika Maezawa and Takeshi Fukuda, Dokkyo Medical
University, Mibu-machi, Tochigi-ken, Japan
1404. Utility of IFN-á As Biomarker in Central Neuropsychiatric
Involvement in SLE. Hilda Fragoso-Loyo, Yemil Atisha-
Fregoso, Carlos Nuñez-Alvarez, Luis LLorente-Peters and
Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias
Médicas y Nutrición Salvador Zubirán, Mexico, Mexico
1405. Peripheral Arterial Disease in Systemic Lupus
Erythematosus. Jose-Gabriel Erdozain 1 , Irama Villar 2 , Javier
Nieto 2 , María-Victoria Egurbide 2 and Guillermo Ruiz-
Irastorza 2 , 1 Hospital de Mendaro, Mendaro, Spain, 2 Hospital
de Cruces, UPV/EHU, Barakaldo, Spain
1406. Characteristics of Disease Activity and Organ System
Involvement in a Cohort of patients with Systemic Lupus
Erythematosus Followed for More Than One Year. Marta
Mosca 1 , Chiara Tani 2 , Linda Carli 1 , Grazia Maria Rizzelli 1 ,
Rossella Neri 1 , Antonio Tavoni 3 , Anna d’Ascanio 4 and Stefano
Bombardieri 4 , 1 University of Pisa, Pisa, Italy, 2 University of
Pisa, Italy, 3 Via Roma 6 7 , Pisa, Italy, 4 Rheumatology Unit,
Pisa, Italy
1407. Medication Impact on Gene Expression Patterns May
Depend on Biologic Subgroups in the Biomarkers of Lupus
Disease (BOLD) Study. Margot O’Toole 1 , Ying Zhang 1 ,
Attila Seyhan 1 , Frederick W. Immermann 2 , Andrew A. Hill 3 ,
Padmalatha S. Reddy 3 , Sudhakar T. Sridharan 2 , Monique
Lehmann 2 , Jaime L. Masferrer 4 , Tianhui Zhou 2 , William M.
Mounts 3 , Maryann Whitley 3 , Terry Walker 1 , Stan Kamp 5 ,
Judith A. James 6 , Marek Honczarenko 1 and Joan T. Merrill 7 ,
1
Pfizer, Cambridge, MA, 2 Pfizer Inc, Collegeville, PA, 3 Pfizer,
Cambridge, 4 Pfizer Inc, Cambridge, MA, 5 Oklahoma Medical
Research Fund, Oklahoma City, 6 Oklahoma Medical Research
Foundation and Oklahoma University Health Sciences
Center, Oklahoma City, OK, 7 Oklahoma Medical Research
Foundation, Oklahoma City, OK
1408. Treatment Regimens of Patients Enrolled in the Lupus
Clinical Trials Consortium (LCTC). Alana B. Levine 1 , Doruk
Erkan 2 , Jill P. Buyon 3 and Michael D. Lockshin 2 , 1 Hospital
for Special Surgery, New York, NY, 2 Barbara Volcker Center
for Women and Rheumatic Diseases, Hospital for Special
Surgery, New York, NY, 3 NYU School of Medicine, New York,
NY
1409. Hydroxychloroquine-Induced Hyperpigmentation in
Patients with Systemic Lupus Erythematosus. A Series of 23
Cases. Moez Jallouli, C. Francès, Jean-Charles Piette, Du Le
Thi Huong, M. Miyara, D. Saadoun, A. Mathian, J. Haroche,
C. De Gennes, G. Leroux, C. Chapelon, Bertrand Wechsler,
Patrice Cacoub, Zahir Amoura and Nathalie Costedoat-
Chalumeau, CHU Pitié-Salpêtrière, Paris, France
1410. Response to Hydroxychloroquine in Japanese Patients
with Cutaneous Lupus Erythematosus Using the
Cutaneous Lupus Erythematosus Disease Area and
Severity Index. Naoto Yokogawa 1 , Takaharu Ikeda 2 , Kyo
Aizawa 3 , Akiko Tanikawa 4 , Masayuki Amagai 4 , Yukihiko
Kato 5 , Yoko Momose 6 , Satoru Arai 6 , Hikaru Eto 6 , Fukumi
Furukawa 2 and Japanese Hydroxychloroquine Study
Group 7 , 1 Tokyo Metropolitan Tama Medical Center, Section
of Rheumatology, Tokyo, Japan, 2 Wakayama Medical
University, Department of Dermatology, Wakayama, Japan,
3
Sanofi-Aventis K.K. Biostatistics & Programming, Tokyo,
Japan, 4 Keio University School of Medicine, Department
of Dermatology, Tokyo, Japan, 5 Tokyo Metropolitan Tama
236
2011 Program Book